Before making decisions to choose the best available treatment for BPH patients, urologists should consider the severity of storage or voiding symptoms, the risk of disease progression (PV, baseline serum PSA level), patient characteristics (age, health condition, concomitant disease, current medication status, and the need for sexual function), individual preferences, and the acceptance of potential side effects. This evidence concerns the gene KLK3 and benign prostatic hyperplasia.